ライフサイエンスコーパス: bile duct cancer

1 ive assessment of the proximal versus distal bile duct cancer.

2 ers also have increased risk of extrahepatic bile duct cancer.

3 lliation and survival in nonresectable hilar bile duct cancer.

4 r (46 000 deaths) and liver and intrahepatic bile duct cancer (41 000 deaths) surpassing colorectal c

5 for gallbladder cancer, 97% of extrahepatic bile duct cancer, 91% of ampula of Vater cancer, 96% of

6 -reactive CD4(+) T cells from a patient with bile duct cancer also exhibited an exhausted phenotype b

7 ectal, lung, ovarian, pancreatic, gastric or bile duct cancer and 245 healthy individuals.

8 able for both toxicity and response: 11 with bile duct cancer and four with gall-bladder carcinoma.

9 m of the secretin receptor in pancreatic and bile duct cancers and developed a dual antibody sandwich

10 ampula of Vater cancer, 96% of intrahepatic bile duct cancer, and 94% of hepatocellular carcinoma.

11 ) arose in the ampulla, 30 (12%) were distal bile duct cancers, and 17 (7%) were duodenal cancers.

12 gene loci and their ligands in patients with bile duct cancer (BDC).

13 g a risk factor for developing an aggressive bile duct cancer, cholangiocarcinoma, in chronically inf

14 gallbladder, intrahepatic, and extrahepatic bile duct cancer compared with the general population.

15 %) extrahepatic and 131 (0.02%) intrahepatic bile duct cancer corresponding to SIRs of 1.58 (95% CI,

16 tionship to the pathogenesis of human distal bile duct cancer (DBDC).

17 associations were observed for extrahepatic bile duct cancer (EHBDC) or ampulla of Vater cancer (AVC

18 Cholangiocarcinoma (CCA) is an epithelial bile duct cancer frequently found at an advanced stage,

19 Cholangiocarcinoma (CCA), a fatal bile duct cancer, has a high incidence in Western Siberi

20 A consecutive cohort of patients with bile duct cancer (hilar, intrahepatic, or distal) was re

21 R=0.77; 95% CI, 0.64-0.91), and intrahepatic bile duct cancer (IHBDC) had an inverse association (HR=

22 individuals; and for liver and intrahepatic bile duct cancer in female individuals (2.05 [1.23-3.44]

23 ts alongside IRRs for liver and intrahepatic bile duct cancer in female individuals, uterine corpus,

24 the development of sclerosing cholangitis or bile duct cancers in XHIM patients.

25 colorectal, liver, pancreas, and gallbladder/bile duct cancers) in 69,310 nonsmoking and non-alcohol-

26 mation, a risk factor for the development of bile duct cancer, induces inducible nitric oxide synthas

27 The incidence of bile duct cancer is low but increasing.

28 Bile duct cancer is the second most common primary liver

29 Liver and intrahepatic bile duct cancer mortality increased for both men and wo

30 mpullary cancer (n = 70; 11%), distal common bile duct cancer (n = 65; 10%), duodenal cancer (n = 26;

31 tail of pancreas, cancer of the extrahepatic bile duct, cancer of the gallbladder, and cancer of the

32 We studied 564 consecutive patients with bile duct cancer operated upon between 1973 and 2004.

33 biliary tract and chronic infection leads to bile duct cancer, or cholangiocarcinoma.

34 (P < .001) and gallbladder and extrahepatic bile duct cancer (P = .01) was observed.

35 rs1126580), was associated with the risk of bile duct cancer (P = 0.003) and biliary stones (P = 0.0

36 oporfin-PDT can safely be delivered to hilar bile duct cancer patients and results in prolonged paten

37 lating to survival times of the leukemia and bile duct cancer patients.

38 for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positi

39 en hepatocellular carcinoma risk factors and bile duct cancer remains to be clarified.

40 IPNBs are an uncommon variant of bile duct cancer, representing approximately 10% of all

41 Cholangiocarcinoma (CCA) is a bile duct cancer that originates in the bile duct epithe

42 range 47-88] years) with nonresectable hilar bile duct cancer were treated with T-PDT (median 1 [rang

43 Hepatocyte, fibrotic lesion, and bile duct (cancer) were classified and HCA mapping showe

44 hepatic cholangiocarcinoma (iCCA) is a fatal bile duct cancer with dismal prognosis and limited thera